Results 41 to 50 of about 72,011 (205)

Hydatidiform mole in Aliero, Nigeria

open access: yes, 2012
Background: Hydatidiform mole is a common complication of gestation.Method: A prospective study of Hydatidiform Mole from October 2005 to November 2006.
Buowari, YD
core   +1 more source

The expression of Ki-67 marker in the hydatidiform mole [PDF]

open access: yes, 2022
Background: The hydatiform mole is charcaterized by a pathological proliferation of the trophoblast. Its evaluation could predict the progression to gestational trophoblastic neoplasia. The aim of the study was the analysis of the proliferative activity
Carpenco, Ecaterina   +9 more
core   +1 more source

Malignancy Risk Factors of Hydatidiform Mole [PDF]

open access: yes, 2019
Objective: to determine risk factors inhydatidiform mole patients who will develop into Gestational Trophoblast Neoplasm (GTN) in Dr.Mohammad Hoesin Hospital Palembang Method: An observational analytical study with case control design was conducted in
Agustria Z Shaleh   +7 more
core   +1 more source

Thyroid function among women with gestational trophoblastic diseases. A cross-sectional study

open access: yesSão Paulo Medical Journal
BACKGROUND: Gestational trophoblastic diseases (GTDs) are treatable rare tumors with wide distribution. The estimated incidence of GTDs varies dramatically between different regions globally.
Harun Düğeroğlu, Murat Özgenoğlu
doaj   +1 more source

Reprogramming of human peripheral blood mononuclear cells from a patient suffering from recurrent hydatidiform mole to an iPSC line FAHZUi001-A carrying a homozygous p.Gln421Ter mutation in NLRP7 gene

open access: yesStem Cell Research, 2021
Recurrent hydatidiform mole (RHM) is characterized by the occurrence of at least twice hydatidiform mole. Unlike sporadic complete hydatidiform moles (CHMs), which are androgenetic with 2 paternal chromosomes, CHMs associated with familial recurrence are
Tingyu Gong   +5 more
doaj   +1 more source

Society for Maternal‐Fetal Medicine Special Statement: Guidance to reduce racial disparities in substance use screening and biological testing in pregnancy at the delivery admission

open access: yesPregnancy, Volume 2, Issue 6, November 2026.
Abstract Substance use complicates upward of 10% of US pregnancies. The Society for Maternal‐Fetal Medicine, the American College of Obstetricians and Gynecologists, and the American Society of Addiction Medicine have jointly recommended universal screening for substance use during pregnancy using a validated tool, without recommending universal ...
Society for Maternal‐Fetal Medicine (SMFM)   +8 more
wiley   +1 more source

Recurrent Partial Hydatidiform Mole: A Case Report of Seven Consecutive Molar Pregnancies

open access: yes, 2023
Siti Salima,1 Mulyohadi Hadi Wibowo,1 Birgitta M Dewayani,2 Aisyah Shofiatun Nisa,1 Firas Farisi Alkaff3,4 1Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran-Dr.
Alkaff FF   +4 more
core  

Early diagnosis and treatment of hydatidiform mole in adolescent pregnant woman [PDF]

open access: yes, 2021
Hydatidiform mole belongs to the spectrum of gestational trophoblastic disorders in which abnormal conception leads to excess placental tissue formation in the absence of fetal development. The incidence of hydatidiform mole is quite rare so that not all
Pramana, Putu Harrista Indra   +3 more
core   +1 more source

GESTATIONAL TROPHOBLASTIC DISEASE IN BASRAH [PDF]

open access: yesThe Medical Journal of Basrah University, 2007
To date few studies have been reported from Basrah regarding Gestational Trophoblastic disease GTD. This study was a clinical observational study done in Basrah at the 4 main obstetric hospitals based on 137 patients with GTD.
Hassna M. Chaied, Zaineb .T. AL Yasin
doaj   +1 more source

Chemotherapy resistance and risk stratification in gestational trophoblastic neoplasia: A systematic review and network meta‐analysis

open access: yesActa Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 11, Page 2158-2172, November 2026.
Higher pretreatment β‐hCG, greater tumor burden, higher FIGO stage/score, and choriocarcinoma were associated with higher chemoresistance risk in gestational trophoblastic neoplasia. In exploratory network analyses, etoposide‐containing regimens showed lower predicted chemoresistance.
Ying‐Ying Xue   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy